Board of Directors

Jeff George

Jeff George has over 25 years of global healthcare and corporate leadership experience across North America, Europe, and emerging markets. He is currently the Managing Partner of Maytal Capital, a healthcare-focused private equity investment and advisory firm he founded in 2017.

Between 2008 and 2016, Jeff served on the Executive Committee of Novartis Group AG, one of the largest global pharmaceutical companies, first as Division Head and CEO of Sandoz, Novartis’s $10 billion generic pharmaceuticals and biosimilars subsidiary which is now publicly listed, and then as Division Head and CEO of Alcon, Novartis’s then $10 billion branded eye-care subsidiary, which was spun out of Novartis in 2019 as an independent company (NYSE: ALC). In both roles, he was responsible for leading over 25,000 associates globally across more than 160 countries.

Jeff previously headed Emerging Markets for the Middle East, Africa, Southeast Asia and CIS at Novartis Pharmaceuticals and served as Vice President and Head of Western & Eastern Europe for Novartis Vaccines. Prior to this, he held leadership roles at Gap Inc. and McKinsey & Co.

Jeff currently serves as Chairman of the Board of Directors at LENZ Therapeutics (Nasdaq: LENZ), an ophthalmic biotech company, and as Chairman of Lykos Therapeutics, a late-stage clinical CNS-focused biopharma company. He also serves on the board of directors of Amneal Pharmaceuticals (Nasdaq: AMRX), a leading specialty and generic pharmaceuticals company, and Dorian Therapeutics, a Silicon Valley-based cellular senescence biotech spun out of Stanford University, as well as on several nonprofit boards.

Jeff holds an MBA from Harvard Business School, a master’s degree from Johns Hopkins University’s School of Advanced International Studies (SAIS), and a bachelor’s degree from Carleton College.